Semnur Pharmaceuticals, Inc. (SMNR)
About Semnur Pharmaceuticals, Inc.
SEMNUR PHARMS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $50.0M
- Net income
- -$160.4M
- Total assets
- $1.3M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Semnur Pharmaceuticals, Inc. (SMNR) Stock Price
- Reported a net loss of $160.4M in FY2024.
- Trading 97% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Semnur Pharmaceuticals, Inc..
Write a review
News about Semnur Pharmaceuticals, Inc.
News & sentiment via Polygon.io
Semnur Pharmaceuticals, Inc.: frequently asked questions
Is Semnur Pharmaceuticals, Inc. an American company?
Semnur Pharmaceuticals, Inc. is a US-based company headquartered in Palo Alto, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Semnur Pharmaceuticals, Inc. headquartered?
Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California, United States.
Is Semnur Pharmaceuticals, Inc. publicly traded?
Yes — Semnur Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol SMNR on the OTC.
What does Semnur Pharmaceuticals, Inc. do?
Semnur Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
